The Drug Discovery and Development Forum 2017 will highlight the challenges to drug discovery and development in the genomics era.
When: June 12th - 16th, 2017
Where: Centre for Translational Biology
McGill University Health Centre
1001 Decarie Boulevard, Bloc E
Montreal, Quebec H4A 3J1
DR. MATTHEW PORTEUS, MD, PHD
Stanford University, School of Medicine
Department of Pediatrics, Hematology/Oncology/Stem Cell Transplantation/Cancer Biology
Stanford, CA. USA
Genetically Engineering Cells as Personalized Drugs to Cure Disease
View abstract
DR. SIDONG HUANG, Assistant Professor
Department of Biochemistry, McGill University
Montreal, Canada
Functional genomics to guide cancer therapy
View abstract
DR. JIE CHENG, Associate Director, Data and Statistical Sciences
AbbVie Inc., Worcester, MA, USA
Systematic evaluation of connectivity map for disease indications
View abstract
DR. BROOKE FRIDLEY, Chair
Department Biostatistics and Bioinformatics, Moffitt Cancer Centre
Tampa, Florida USA
Data Science in the Age of Cancer Genomics and Drug Discovery
View abstract
DR. CHI-YING HUANG, Chair
Institute of Biopharmaceutical Sciences, National Yang Ming University
Taipei, Taiwan
Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using big data analysis
View abstract
DR. ARAVIND SUBRAMANIAN, Director Biomedical Science Connectivity Map, LINCS & L1000
Broad Institute of MIT & Harvard
Cambridge, MA, USA
A Next Generation Connectivity Map using the L1000 platform
View abstract
DR. KOLJA EPPERT, Leukemia Stem Cells, Cancer
MUHC Pediatric Hematology-Oncology - Glen site, McGill University
Montreal, Canada
Novel Therapeutics to Target Stem Cells in Acute Myeloid Leukemia
View abstract
KENNETH EMANCIPATOR, MD, DABP
Executive Medical Director & Head of Companion Diagnostics Translational Medicine, Physician, in vitro companion diagnostic device expert, Merck & Co.
Kenilworth NJ, USA
Developing an Immunohistochemistry Test for Programmed Cell Death Ligand 1 (PD-L1) as a Companion Diagnostic for Pembrolizumab
View abstract
RUI MANUEL REIS, PHD
Coordinator, Molecular Oncology Research Center Barretos Cancer Hospital - Barretos
Sao Paulo, Brazil
Efficacy and predict biomarkers of response of Affitinib, a second generation of anti-HER agent.
View abstract
PROF JOHN HARTLEY, Director Cancer Research
UK Drug-DNA-Interactions Research Group, UCL Cancer Institute
London, U.K.
The development of novel therapies involving DNA as a target
View abstract
YVES POMMIER, M.D., PH.D. NCI
Center for Cancer Research – National Cancer Institute
Bethesda, MD USA
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
View abstract
For more information, please contact us at:
Tel: (514)934-1934 ext. 76435
Trainingindrugdev.med@mcgill.ca
Dr. Bertrand J. Jean-Claude
Dr. Janusz Rak
Dr. Bassam Adulkarim
Dr. Koja Eppert